HC Wainwright Forecasts AxoGen’s Q1 Earnings (NASDAQ:AXGN)

AxoGen, Inc. (NASDAQ:AXGN) – Stock analysts at HC Wainwright reduced their Q1 2027 EPS estimates for AxoGen in a research report issued on Thursday, July 30th. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will post earnings of $0.04 per share for the quarter, down from their prior estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $53.00 price target on the stock. The consensus estimate for AxoGen’s current full-year earnings is ($0.37) per share.

Several other research firms also recently issued reports on AXGN. Zacks Research upgraded shares of AxoGen from a “strong sell” rating to a “hold” rating in a research note on Friday, May 29th. Citigroup reiterated a “market outperform” rating on shares of AxoGen in a research report on Thursday. Citizens Jmp raised their price target on AxoGen from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a research report on Friday, May 29th. Finally, Wells Fargo & Company upped their price objective on AxoGen from $40.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, AxoGen currently has a consensus rating of “Moderate Buy” and an average price target of $51.00.

AxoGen Trading Up 8.3%

Shares of AxoGen stock opened at $45.73 on Tuesday. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07. The company has a fifty day simple moving average of $42.23 and a 200-day simple moving average of $37.51. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -67.25 and a beta of 1.11. AxoGen has a 12-month low of $12.39 and a 12-month high of $46.95.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The firm had revenue of $69.73 million during the quarter, compared to the consensus estimate of $67.10 million.

Institutional Investors Weigh In On AxoGen

A number of hedge funds have recently added to or reduced their stakes in AXGN. MCF Advisors LLC purchased a new stake in AxoGen in the 4th quarter valued at approximately $30,000. Aquatic Capital Management LLC raised its stake in shares of AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 1,269 shares in the last quarter. Arax Advisory Partners raised its stake in shares of AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 819 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of AxoGen in the 4th quarter valued at approximately $36,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of AxoGen in the fourth quarter valued at approximately $39,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

Insiders Place Their Bets

In other news, Director Kathy Johnson Weiler sold 16,344 shares of AxoGen stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $44.09, for a total value of $720,606.96. Following the sale, the director owned 16,344 shares of the company’s stock, valued at $720,606.96. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John Johnson sold 11,050 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $43.26, for a total transaction of $478,023.00. Following the transaction, the director owned 11,050 shares in the company, valued at approximately $478,023. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 29,041 shares of company stock worth $1,268,792. 2.44% of the stock is owned by insiders.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.